Advertisement
Advertisement
Aclaris Therapeutics, Inc. (ACRS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 15.85 |
| Open | 16.04 |
| Bid | 5.80 x 1200 |
| Ask | 14.99 x 1100 |
| Day's Range | 14.33 - 16.25 |
| 52 Week Range | 9.26 - 19.97 |
| Volume | |
| Avg. Volume | 501,174 |
| Market Cap | 882.898M |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Here is how Aclaris Therapeutics (ACRS) and Alkermes (ALKS) have performed compared to their sector so far this year.
- Zacks
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- Zacks
Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect?
The consensus price target hints at a 141% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
